Journal
BIOMATERIALS
Volume 30, Issue 23-24, Pages 3956-3960Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2009.04.020
Keywords
Hydroxyapatite; Hydroxyapatite composite; Nanocomposite; Nanoparticle; Chemotherapy
Funding
- National Science Council [NSC 96-2314-B-002-080-MY3]
- National Taiwan University Hospital, Yun-Lin Branch [NTUHYL98.M001]
Ask authors/readers for more resources
Hyperthermia therapy for cancer has drawn more and more attention these days. In this study, we conducted an in vivo cancer hyperthermia study of the new magnetic hydroxyapatite nanoparticles by a mouse model. The magnetic hydroxyapatite nanoparticles were first made by co-precipitation method with the addition of Fe2+. Then, magnetic-HAP powder (mHAP) or pure HAP powder (HAP) was mixed with phosphate buffer solution (PBS), respectively. The mixture was injected around the tumor. In order to achieve hyperthermia. the mice were placed into an inductive heater with high frequency and alternating magnetic field. Only the mice which were injected with mHAP and had been treated inside the magnetic field showed dramatic reduction of tumor volume, in the 15-day observation period. No local recurrence was noted. The blood test of mice proved that mHAP powders possessed good biocompatibility and little toxicity when injected subcutaneously. Therefore, our new magnetic hydroxyapatite nanoparticles have demonstrated therapeutic effect in a mouse model with little toxicity. Further study should be done before its application inside the human body. (C) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available